Drug Trial Radar · NCT04633122
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
108
Actual
Start
Nov 25, 2020
Primary completion
Jul 20, 2022
Study completion Jul 20, 2022
Sponsor
- Lead sponsor
- Zai Lab (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
the primary objective of this study is to assess the efficacy (progression-free survival,PFS) of DCC-2618 (ripretinib, ZL-2307) and sunitinib in patients with advanced gastrointestinal stromal tumors after treatment with imatinib. This study will enroll approximately 98 subjects in around 18 sites in China mainland, and all subjects will be receiving DCC-2618 or Sunitinib in equal chance as treatment.
Conditions
- Gastrointestinal Stromal Tumor(GIST)
Interventions
RipretinibDrug
Oral kinase inhibitor
SunitinibDrug
second-line therapy in GIST patients who have progressed after imatinib treatment or are intolerant to imatinib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Approximately 12 months.
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
The General Hospital of Peking University
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Chongqing Medical Universty
Chongqing, Chognqing, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
The Cancer Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
The sixth Affiliated hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
The 4th Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The Affiliated Hospital of Haerbin MedicalUniversity
Harbin, Heilongjiang, China
Union Hospital of HUST
Wuhan, Hubei, China
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, China
Fudan University, Zhongshan Hospital
Shanghai, Shanghai Municipality, China
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
The Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.